王蕾①, 吴峥②, 程皖琴③, 周树①, 钟睿①, 曾睿芳④, 苏勇①. 局部中晚期鼻咽癌四程诱导化疗后肿瘤靶区勾画的研究[J]. 中国肿瘤临床, 2016, 43(22): 986-991. DOI: 10.3969/j.issn.1000-8179.2016.22.696
引用本文: 王蕾①, 吴峥②, 程皖琴③, 周树①, 钟睿①, 曾睿芳④, 苏勇①. 局部中晚期鼻咽癌四程诱导化疗后肿瘤靶区勾画的研究[J]. 中国肿瘤临床, 2016, 43(22): 986-991. DOI: 10.3969/j.issn.1000-8179.2016.22.696
Lei WANG1, Zheng WU2, Wanqin CHENG3, Shu ZHOU1, Rui ZHONG1, Ruifang ZENG4, Yong SU1. Target volume delineation in locoregionally advanced nasopharyngeal carcinoma after four circles of induction chemotherapy[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 43(22): 986-991. DOI: 10.3969/j.issn.1000-8179.2016.22.696
Citation: Lei WANG1, Zheng WU2, Wanqin CHENG3, Shu ZHOU1, Rui ZHONG1, Ruifang ZENG4, Yong SU1. Target volume delineation in locoregionally advanced nasopharyngeal carcinoma after four circles of induction chemotherapy[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 43(22): 986-991. DOI: 10.3969/j.issn.1000-8179.2016.22.696

局部中晚期鼻咽癌四程诱导化疗后肿瘤靶区勾画的研究

Target volume delineation in locoregionally advanced nasopharyngeal carcinoma after four circles of induction chemotherapy

  • 摘要: 目的:探讨根据诱导化疗后肿瘤变化勾画靶区的方式及其临床疗效。方法:回顾性分析2009 年8 月至2013 年8 月中山大学肿瘤防治中心 57 例局部中鼻咽癌患者,行诱导化疗联合同期放化疗。诱导化疗前后鼻咽原发肿瘤范围(gross tumor volume,GTV )(包括咽后淋巴结)分别为GTVnx-pre 和GTVnx-post 。临床靶区(clinical tumor volume,CTV )CTVnx 1 为GTVnx-post 外扩10 mm范围,并包括 GTVnx-pre的区域。颈部淋巴结的靶区勾画与上述方法相似,分别命名为 GTVnd-pre、GTVnd-post 和CTVnd 1。CTV 2 为CTVnx 1及CTVnd 1 外扩 5 mm~10 mm范围及淋巴引流选择性预防照射范围。观察全组患者不良反应、近期及远期疗效。结果:GTVnx-pre和GTVnx-post 平均体积分别为 63 .7 cm3和21 .8 cm3(P<0.01 );GTVnd-pre和GTVnd-post 平均体积分别为 21 .7 cm3和7.5 cm3(P<0.01 )。中位随访时间60 .0 个月,全组患者 5 年总生存率(overall survival ,OS)为86 .0%(49 /57 ),无远处转移生存率(distant metastasis free survival rate ,DMFS)为91 .2%(52 /57 ),无局部复发生存率(local recurrence survival rate ,LRFS)为93 .0%(53 /57 ),无进展生存率(progression free survival,PFS)为93 .0%(53 /57 ),复发患者均为GTVnx-post 或GTVnd-post 内复发。结论:鼻咽癌4 个疗程诱导化疗后肿瘤体积明显缩小,按化疗后肿瘤勾画靶区疗效较好,值得进一步验证。

     

    Abstract: Objective:To investigate target volume delineation after four cycles of induction chemotherapy in locoregionally advanced nasopharyngeal cancer (NPC).Methods:From August2009to August 2013, 57patients with stage Ⅲ- ⅣNPC were treated with induc -tion-concurrent chemotherapy and intensity-modulated radiotherapy. The primary gross tumor volume (GTV), including retropharyn -geal lymph node metastasis before and after induction chemotherapy, was defined as GTVnx- pre and GTVnx- post, respectively, and the clinical target volume (CTV) was divided into two parts: CTV1 and CTV2. The CTVnx 1 was defined as the GTVnx-post plus a10-mm margin, covering the region of GTVnx-pre. The contouring of neck lymph nodes was similar to the primary gross tumor, with the neck lymph nodes GTV and CTV defined as GTVnd- pre, GTVnd- post, and CTVnd1, respectively. CTV 2 was defined as CTVnx1 and CTVnd1 plus a 5- mm margin together with the bilateral cervical selective lymph drainage respectively areas. Treatment outcome and toxicity were determined in all patients.Results:The GTVnx- post was significantly smaller than the GTVnx- pre ( 21. 8 cm3 vs . 63. 7 cm3 , P<0. 01), whereas the GTVnd-post was significantly smaller than the GTVnd-pre (21. 7 cm3 vs . 7. 5 cm3, P<0. 01). With a median follow-up of 60. 0 months, the 5-year overall survival (OS), locoregional relapse-free survival (LRFS), distant metastasis-free survival (DMFS), and progres -sion-free survival (PFS) rates were 49/57(86. 0%),53/57(93. 0%),52/57(91. 2%), and53/57(93. 0%) respectively. All locoregional fail ures occurred in the GTVnx-post or GTVnd-post field with no relapses in the CTVnx1 or CTVnd 1. Conclusion: Four cycles of IC can signif -icantly reduce tumor volume. The target volume delineation according to the tumor volume after IC has encouraging long-term treat -ment outcome.

     

/

返回文章
返回